A Study of HS-10383 in Chinese Adult Subjects With Refractory or Unexplained Chronic Cough (RUCC)

Cough Clinical Trial

Official title:

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-designed Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of HS-10383 in Chinese Adult Subjects With Refractory or Unexplained Chronic Cough (RUCC)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06246565
• Other study ID #: HS-10383-201
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: March 1, 2024
• Est. completion date: June 1, 2026

Study information

• Verified date: January 2024
• Source: Jiangsu Hansoh Pharmaceutical Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-designed phase 2 clinical trial to evaluate the efficacy, safety and pharmacokinetic (PK) characteristics of HS-10383 in Chinese adult subjects with refractory or unexplained chronic cough (RUCC).

Description:

The primary objectives of this study are to evaluate the efficacy of HS-10383 in reducing cough frequency as measured over a 24-hour period, and to determine the safety and tolerability of HS-10383. The primary hypothesis is that at least one dose of HS-10383 is superior to placebo in reducing coughs per hour (over 24 hours) at Week 4.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 276
• Est. completion date: June 1, 2026
• Est. primary completion date: September 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Subjects should have a full understanding of the study contents, process, and possible adverse reactions, and voluntarily sign the informed consent form;

2. Subjects aged 18-70 years (including the critical value) with RUCC =1 year (diagnosis of RUCC according to the Expert Consensus on Diagnosis and Treatment of Refractory Chronic Cough in China [Released in 2021]);

3. Subjects whose serum pregnancy test is negative in both screening and baseline visits;

Exclusion Criteria:

1. Subjects who are diagnosed with chronic obstructive pulmonary disease, bronchiectasis, idiopathic pulmonary fibrosis and other serious lung diseases;

2. Any physiological or mental disease or condition that may increase study risks or interfere with the conduct of the study or affect the ability to complete this study in the opinion of the investigator, such as medical history of depression;

3. Subjects who cannot meet the requirements for piror treatment or who cannot adhere to the concomitant treatment as specified in Section 6.7-Prior/concomitant medications and non-drug treatment.

4. Subjects with positive hepatitis A IgM antibody, hepatitis C antibody (HCVAb), syphilis antibody or human immunodeficiency virus (HIV) antibody at screening visit; subjects with positive hepatitis B surface antigen (HBsAg) at screening (except for quantitative detection result of HBV-DNA is below the lower limit of the detection reference range).

5. Any former smoker with more than 20 packs/year; or have quited smoking for less than 6 months; or subjects who are still smoking (including e-cigarettes);

6. Subjects who have a history of serious drug, food or environmental allergies, or who are known to be allergic to the ingredients of investigational product;

7. History of drug dependence,drug or alcohol abuse in the past year;

8. Female subjects who are pregnant or breastfeeding;

9. Subjects who have previously received anything that may affect drug absorption, including but not limited to: gastrectomy, gastroplasty, any type of weight-loss surgery, vagotomy or enterotomy;

10. Subjects who have been vaccinated within 30 days before screening visit, or have a vaccination plan during the whole study period.

Related Conditions & MeSH terms

• Chronic Cough
• Cough

Intervention

Drug:
• HS-10383
HS-10383 administered as one 50 mg, 100 mg 200 mg tablet once daily, depending upon randomization.
• HS-10383 Placebo
HS-10383 administered as one 50 mg, 100 mg 200 mg tablet once daily, depending upon randomization.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	24-Hour Cough Frequency	Assessed using an ambulatory cough monitor	at Week 4
Secondary	Awake Cough Frequency	Change from baseline in awake cough frequency at week 4;	at Week 4
Secondary	Change from Baseline in Cough Severity Visual Analogue Scale at Week 2 and Week 4;	Assessed by Cough Severity Visual Analogue Scale [VAS] by the participant on a 100 mm visual analog scale where higher scores indicate greater severity.	at Week 2 and Week 4
Secondary	Change from Baseline in the Leicester Cough Questionnaire (LCQ) Total Score at Week 2 and Week 4.	The LCQ is a patient-reported quality of life (QOL) measure of chronic cough,the higher scores mean a better outcome.	at Week 2 and Week 4